Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Obesity Surgery
Published in: Obesity Surgery 10/2011

01-10-2011 | Clinical Research

Morbidly Obese are Ghrelin and Leptin Hyporesponders with Lesser Intragastric Balloon Treatment Efficiency

Ghrelin and Leptin Changes in Relation to Obesity Treatment

Authors: Marko Nikolic, Marko Boban, Neven Ljubicic, Vladimir Supanc, Gorana Mirosevic, Borka Pezo Nikolic, Ruzica Krpan, Ljubica Posavec, Vanja Zjacic-Rotkvic, Miroslav Bekavac-Beslin, Petar Gacina

Published in: Obesity Surgery | Issue 10/2011

Login to get access

Abstract

Background

Ghrelin and leptin recently emerged as the most influential neuroendocrine factors in the pathophysiology of obesity. The said peptides act in reciprocity and are responsible for regulation of appetite and energy metabolism. Intragastric balloons acquired worldwide popularity for obesity treatment. However, the roles of ghrelin and leptin in intragastric balloon treatment were still not systematically studied.

Methods

A prospective single-center study included 43 Caucasians treated with BioEnterics intragastric balloon, with age range of 18–60, and divided to non-morbid (body mass index cutoff 40 kg/m2) or morbid type of obesity, with 12 months follow-up. Serum hormonal samples were taken from fasting patients and kept frozen until analyses.

Results

Significant differences were observed in anthropometrics and there were no differences between genders or comorbidities. The baseline weight for non-morbid vs. morbid was 104 kg (90–135) vs. 128.5 kg (104–197). Weight loss was statistically different between the studied groups during the study course with a median control weight at 6 months of 92 kg (72–121) vs. 107 kg (84–163), p < 0.001. Treatment was successful for 18 (94.7%) vs. 16 (66.7%) patients, p = 0.026. Ghrelin varied from 333.3 to 3,416.8 pg/ml and leptin from 1.7 to 61.2 ng/ml, with a statistically significant time-dependent relationship. A significant difference (p = 0.04) with emphasized ghrelin peak was found in the 3rd month of treatment for non-morbidly obese subjects.

Conclusions

The importance of ghrelin and leptin in treatment-induced changes was reaffirmed. Ghrelin hyper-response in non-morbidly obese subjects characterized greater short-term treatment efficiency and landmarked an inclination to weight regain. The results suggest a potential pattern of individualization between obese patients according to body mass index towards intragastric balloon or bariatric surgery. Further studies are needed in order to get better insights in the pathophysiologic mechanisms of obesity.
Literature
1.
Mathus-Vliegen EM. Obesity: intragastric balloons—a bubble to combat the obesity bubble? Nat Rev Gastroenterol Hepatol. 2010;7:7–8.PubMedCrossRef
2.
Dumonceau JM, Francois E, Hittelet A, et al. Single vs repeated treatment with the intragastric balloon: a 5-year weight loss study. Obes Surg. 2010;20:692–7.PubMedCrossRef
3.
Dastis NS, Francois E, Deviere J, et al. Intragastric balloon for weight loss: results in 100 individuals followed for at least 2.5 years. Endoscopy. 2009;41:575–80.PubMedCrossRef
4.
Herve J, Wahlen CH, Schaeken A, et al. What becomes of patients one year after the intragastric balloon has been removed? Obes Surg. 2005;15:864–70.PubMedCrossRef
5.
Dumonceau JM. Evidence-based review of the BioEnterics intragastric balloon for weight loss. Obes Surg. 2008;18:1611–7.PubMedCrossRef
6.
Tschop M, Weyer C, Tataranni PA, et al. Circulating ghrelin levels are decreased in human obesity. Diabetes. 2001;50:707–9.PubMedCrossRef
7.
Havel PJ. Peripheral signals conveying metabolic information to the brain: short-term and long-term regulation of food intake and energy homeostasis. Exp Biol Med (Maywood). 2001;226:963–77.
8.
Davis JF, Choi DL, Schurdak JD, et al. Leptin regulates energy balance and motivation through action at distinct neural circuits. Biol Psychiatry. 2010;69:668–74.PubMedCrossRef
9.
Mion F, Napoleon B, Roman S, et al. Effects of intragastric balloon on gastric emptying and plasma ghrelin levels in non-morbid obese patients. Obes Surg. 2005;15:510–6.PubMedCrossRef
10.
Konopko-Zubrzycka M, Baniukiewicz A, Wroblewski E, et al. The effect of intragastric balloon on plasma ghrelin, leptin, and adiponectin levels in patients with morbid obesity. J Clin Endocrinol Metab. 2009;94:1644–9.PubMedCrossRef
11.
Martinez-Brocca MA, Belda O, Parejo J, et al. Intragastric balloon-induced satiety is not mediated by modification in fasting or postprandial plasma ghrelin levels in morbid obesity. Obes Surg. 2007;17:649–57.PubMedCrossRef
12.
Tymitz K, Engel A, McDonough S, et al. Changes in ghrelin levels following bariatric surgery: review of the literature. Obes Surg. 2011;21:125–30.PubMedCrossRef
13.
Tschop M, Wawarta R, Riepl RL, et al. Post-prandial decrease of circulating human ghrelin levels. J Endocrinol Investig. 2001;24:RC19–21.
14.
Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:i–xii, 1–253.
15.
Favretti F, Mazrizio DL, Segato G, et al. The BioEnterics intragastric balloon for the nonsurgical treatment of obesity and morbid obesity. In: Schauer PR, Schirmer BD, Brethauer SA, et al., editors. Minimally invasive bariatric surgery. New York: Springer; 2007.
16.
17.
Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402:656–60.PubMedCrossRef
18.
Date Y, Kojima M, Hosoda H, et al. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology. 2000;141:4255–61.PubMedCrossRef
19.
Ariyasu H, Takaya K, Tagami T, et al. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab. 2001;86:4753–8.PubMedCrossRef
20.
Sakata I, Nakamura K, Yamazaki M, et al. Ghrelin-producing cells exist as two types of cells, closed- and opened-type cells, in the rat gastrointestinal tract. Peptides. 2002;23:531–6.PubMedCrossRef
21.
Murray CD, Kamm MA, Bloom SR, et al. Ghrelin for the gastroenterologist: history and potential. Gastroenterology. 2003;125:1492–502.PubMedCrossRef
22.
Gualillo O, Caminos J, Blanco M, et al. Ghrelin, a novel placental-derived hormone. Endocrinology. 2001;142:788–94.PubMedCrossRef
23.
Drazen DL, Vahl TP, D’Alessio DA, et al. Effects of a fixed meal pattern on ghrelin secretion: evidence for a learned response independent of nutrient status. Endocrinology. 2006;147:23–30.PubMedCrossRef
24.
Faraj M, Havel PJ, Phelis S, et al. Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab. 2003;88:1594–602.PubMedCrossRef
25.
Lopez-Nava G, Rubio MA, Prados S, et al. BioEnterics(R) intragastric balloon (BIB(R)). Single ambulatory center Spanish experience with 714 consecutive patients treated with one or two consecutive balloons. Obes Surg. 2011;21:5–9.PubMedCrossRef
26.
Genco A, Cipriano M, Bacci V, et al. Intragastric balloon followed by diet vs intragastric balloon followed by another balloon: a prospective study on 100 patients. Obes Surg. 2010;20:1496–500.PubMedCrossRef
27.
Suzuki H, Hibi T. Does Helicobacter pylori attack ghrelin-producing cells? J Gastroenterol. 2005;40:437–9.PubMedCrossRef
28.
Fruhbeck G, Diez Caballero A, Gil MJ. Fundus functionality and ghrelin concentrations after bariatric surgery. N Engl J Med. 2004;350:308–9.PubMedCrossRef
29.
Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372:425–32.PubMedCrossRef
30.
Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996;334:292–5.PubMedCrossRef
31.
Ahren B, Baldwin RM, Havel PJ. Pharmacokinetics of human leptin in mice and rhesus monkeys. Int J Obes Relat Metab Disord. 2000;24:1579–85.PubMedCrossRef
32.
Soderberg S, Ahren B, Jansson JH, et al. Leptin is associated with increased risk of myocardial infarction. J Intern Med. 1999;246:409–18.PubMedCrossRef
33.
Soderberg S, Ahren B, Stegmayr B, et al. Leptin is a risk marker for first-ever hemorrhagic stroke in a population-based cohort. Stroke. 1999;30:328–37.PubMedCrossRef
34.
Havel PJ. Role of adipose tissue in body-weight regulation: mechanisms regulating leptin production and energy balance. Proc Nutr Soc. 2000;59:359–71.PubMedCrossRef
35.
Levin N, Nelson C, Gurney A, et al. Decreased food intake does not completely account for adiposity reduction after ob protein infusion. Proc Natl Acad Sci USA. 1996;93:1726–30.PubMedCrossRef
36.
Licinio J, Caglayan S, Ozata M, et al. Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. Proc Natl Acad Sci USA. 2004;101:4531–6.PubMedCrossRef
37.
Rosenbaum M, Goldsmith R, Bloomfield D, et al. Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. J Clin Invest. 2005;115:3579–86.PubMedCrossRef
38.
Nikolic M, Mirosevic G, Ljubicic N, et al. Obesity treatment using a BioEnterics intragastric balloon (BIB)—preliminary Croatian results. Obes Surg. 2010. doi:10.​1007/​s11695-010-0101-7.
39.
Sallet JA, Marchesini JB, Paiva DS, et al. Brazilian multicenter study of the intragastric balloon. Obes Surg. 2004;14:991–8.PubMedCrossRef
40.
Mathus-Vliegen EM. Intragastric balloon treatment for obesity: what does it really offer? Dig Dis. 2008;26:40–4.PubMedCrossRef
41.
Genco A, Cipriano M, Materia A, et al. Laparoscopic sleeve gastrectomy versus intragastric balloon: a case–control study. Surg Endosc. 2009;23:1849–53.PubMedCrossRef
42.
Melissas J, Mouzas J, Filis D, et al. The intragastric balloon—smoothing the path to bariatric surgery. Obes Surg. 2006;16:897–902.PubMedCrossRef
Metadata
Title
Morbidly Obese are Ghrelin and Leptin Hyporesponders with Lesser Intragastric Balloon Treatment Efficiency
Ghrelin and Leptin Changes in Relation to Obesity Treatment
Authors
Marko Nikolic
Marko Boban
Neven Ljubicic
Vladimir Supanc
Gorana Mirosevic
Borka Pezo Nikolic
Ruzica Krpan
Ljubica Posavec
Vanja Zjacic-Rotkvic
Miroslav Bekavac-Beslin
Petar Gacina
Publication date
01-10-2011
Publisher
Springer-Verlag
Published in
Obesity Surgery / Issue 10/2011
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-011-0414-1

Other articles of this Issue 10/2011

Obesity Surgery 10/2011 Go to the issue

Clinical Report

Morbidity in Patients with or at High Risk for Obstructive Sleep Apnea after Ambulatory Laparoscopic Gastric Banding

Letter to the Editor

Pregnancy May Increase the Risk of Proximal Gastric Pouch Dilatation after LAGB Surgery

Clinical Report

Examination of the Efficacy and Safety of Intraoperative Gastroscopic Testing of the Gastrojejunal Anastomosis in Laparoscopic Roux Y Gastric Bypass Surgery

Short Communication

Decreased Serum Betaine Concentrations in Patients after Bariatric Surgery

Current Status

Experimental Metabolic Surgery: Justification and Technical Aspects

Basic Science Research

Depletion of Serum Carotenoid and Other Fat-Soluble Vitamin Concentrations following Obesity Surgery